Search research articles
Contact Us
Filters
Showing results (1-10 of 69) with videos related to
Page
of 7
Sort By:
Seminars in Oncology
|
April 1, 2009
Progress in gynecologic cancer
Michael V Seiden
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 30, 2013
Rare epithelial tumors arising in or near the ovary: a review of the risk factors, presentation, and future treatment direction for ovarian clear cell and mucinous carcinoma
Angela Jain, Michael V Seiden
The Oncologist
|
October 27, 2005
Topotecan: weighing in when there are many options
Richard T Penson, Michael V Seiden
The American Journal of Managed Care
|
March 17, 2017
Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value
Michael V Seiden, Marcus Neubauer, Diana Verrilli
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
August 11, 2001
cDNA Technologies and their application to drug resistance research: power, potential and problems
Zhenfeng Duan, Diana E. Lamendola, Michael V. Seiden
Molecular Cancer Therapeutics
|
July 15, 2004
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells
Zhenfeng Duan, Katherine A Brakora, Michael V Seiden
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2012
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location
Angela Jain, Paula D Ryan, Michael V Seiden
Gene
|
November 24, 2004
MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines
Zhenfeng Duan, Katherine A Brakora, Michael V Seiden
Current Treatment Options in Oncology
|
February 19, 2005
Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies
Ami P Vaidya, Aric D Parnes, Michael V Seiden
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles
Harikrishna Devalapally, Zhenfeng Duan, Michael V Seiden, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 69) with videos related to
Sort By:
Page
of 7
Seminars in Oncology
|
April 1, 2009
Progress in gynecologic cancer
Michael V Seiden
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 30, 2013
Rare epithelial tumors arising in or near the ovary: a review of the risk factors, presentation, and future treatment direction for ovarian clear cell and mucinous carcinoma
Angela Jain, Michael V Seiden
The Oncologist
|
October 27, 2005
Topotecan: weighing in when there are many options
Richard T Penson, Michael V Seiden
The American Journal of Managed Care
|
March 17, 2017
Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value
Michael V Seiden, Marcus Neubauer, Diana Verrilli
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
August 11, 2001
cDNA Technologies and their application to drug resistance research: power, potential and problems
Zhenfeng Duan, Diana E. Lamendola, Michael V. Seiden
Molecular Cancer Therapeutics
|
July 15, 2004
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells
Zhenfeng Duan, Katherine A Brakora, Michael V Seiden
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2012
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location
Angela Jain, Paula D Ryan, Michael V Seiden
Gene
|
November 24, 2004
MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines
Zhenfeng Duan, Katherine A Brakora, Michael V Seiden
Current Treatment Options in Oncology
|
February 19, 2005
Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies
Ami P Vaidya, Aric D Parnes, Michael V Seiden
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles
Harikrishna Devalapally, Zhenfeng Duan, Michael V Seiden, et al.
Page
of 7